Pre–commercial Procurement to buy R&D Services to Early Detecting Micro‐organisms that may Determine the Incurrence of Hospital-Acquired Infections and to Controlling the Diffusion of Infections

Agència de Qualitat i Avaluació Sanitària de Catalunya

This Contract Notice invites interested operators to submit tenders to a procurement.
The procurement aims to trigger new solutions to be developed and tested to address the following challenges:
— reducing both the healthcare and governmental costs and the operational impact resulting from infections caused by MDROs,
— improving the appropriateness and effectiveness of antimicrobial medicine usage,
— reducing the community and social care impact of MDROs acquired at hospitals through technologies that will transform current surveillance and Infections control systems into new comprehensive systems.
This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).

Plazo

El plazo para la recepción de ofertas era de 2019-10-28. La contratación se publicó en 2019-07-23.

Proveedores

Los siguientes proveedores se mencionan en decisiones de adjudicación u otros documentos de contratación:

¿A quién?

• Agència de Qualitat i Avaluació Sanitària de Catalunya

¿Cómo?

¿dónde?

• Cataluña › Barcelona

Historial de adquisiciones

Fecha	Documento
2019-07-23	Anuncio de licitación
2020-03-17	Anuncio de adjudicación de contrato

Anuncio de licitación (2019-07-23)
Objeto
Alcance de la contratación
Título: Servicios de investigación y desarrollo experimental
Breve descripción:

This Contract Notice invites interested operators to submit tenders to a procurement. The procurement aims to trigger new solutions to be developed and tested to address the following challenges: — reducing both the healthcare and governmental costs and the operational impact resulting from infections caused by MDROs, — improving the appropriateness and effectiveness of antimicrobial medicine usage, — reducing the community and social care impact of MDROs acquired at hospitals through technologies that will transform current surveillance and Infections control systems into new comprehensive systems. This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).

Metadatos del anuncio
Idioma original: inglés 🗣️
Tipo de documento: Anuncio de licitación
Naturaleza del contrato: Servicios
Reglamentación: Unión Europea
Vocabulario común de contratación pública (CPV)
Código: Servicios de investigación y desarrollo experimental 📦
Código CPV adicional: Servicios de investigación y desarrollo experimental 📦
Lugar de ejecución
Región NUTS: Cataluña 🏙️

Procedimiento
Tipo de procedimiento: Procedimiento abierto
Tipo de oferta: Oferta para todos los lotes
Criterios de adjudicación
Oferta más económica

Autoridad contratante
Identidad
País: España 🇪🇸
Tipo de poder adjudicador: Oficina/entidad regional o local
Nombre del poder adjudicador: Agència de Qualitat i Avaluació Sanitària de Catalunya
Dirección postal: C. Roc Boronat, 81-95
Código postal: 08005
Ciudad postal: Barcelona
Contacto
Dirección de internet: http://antisuperbugs.eu/ 🌏
Correo electrónico: contractes.aquas@gencat.cat 📧
Teléfono: +34 935513943 📞
Fax: +34 935517510 📠
URL de los documentos: https://contractaciopublica.gencat.cat/ecofin_pscp/AppJava/perfil/AQuAS 🌏
URL de participación: https://contractaciopublica.gencat.cat/ecofin_pscp/AppJava/perfil/AQuAS 🌏

Referencia
Fechas
Fecha de envío: 2019-07-23 📅
Fecha límite de presentación: 2019-10-28 📅
Fecha de publicación: 2019-07-25 📅
Identificadores
Número de anuncio: 2019/S 142-349721
Se refiere al anuncio: 2017/S 197-404917
Número del DO-S: 142
Información complementaria

Participation in the open market consultation that was held as part of the preparation for this procurement is not a prerequisite for submitting a tender. This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs. Publication of this Contract Notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation. The open procedure was chosen in Section IV.1.1) ‘Procedure’ for formal reasons only. This is because it is not possible to publish a contract notice without selecting one of the listed procedures. Offers may be submitted in English and either Catalan or Spanish (please read the request for tenders document). All communication (before, during and after the procurement) can be made in English, Spanish and Catalan (please read the request for tenders document). See: The project website http://antisuperbugs.eu/ The open market consultation Q&A http://antisuperbugs.eu/index.php/market-consultation-2/ PCPs on the Europa website (see https://ec.europa.eu/digital-single-market/innovation-procurement) or contact: antisuperbugs.AQUAS@gencat.cat

Objeto
Alcance de la contratación
Breve descripción:

This Contract Notice invites interested operators to submit tenders to a procurement.

The procurement aims to trigger new solutions to be developed and tested to address the following challenges:

— reducing both the healthcare and governmental costs and the operational impact resulting from infections caused by MDROs,

— improving the appropriateness and effectiveness of antimicrobial medicine usage,

— reducing the community and social care impact of MDROs acquired at hospitals through technologies that will transform current surveillance and Infections control systems into new comprehensive systems.

This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).

Valor total estimado: 2848450.41 EUR 💰
Breve descripción:

This is a joint procurement involving different countries, and the state applicable national procurement law is the Spanish one.

The lead procurer (Agència de Qualitat i Avaluació Sanitària de Catalunya) is appointed to coordinate and lead the joint PCP, and to sign and award the framework agreement and the specific contracts for all phases of the PCP, in the name and on behalf of the following buyers group:

— ICO/ VINCat (Catalan Institute of Oncology/Catalan Nosocomial Infections Surveillance). Spain,

— UKA (Aachen University Hospital). Germany,

— STH (Sheffield Teaching Hospitals NHS Foundation Trust. UK,

— PAT (Provincia Autonoma di Trento). Italy,

— Helios (Helios Universitätsklinikum Wuppertal). Germany,

— FMT (Fundació Mutua de Terrassa). Spain.

The lead procurer is not part of the buyers group.

The procurement will take the form of a pre-Commercial Procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.

Each selected operator will be awarded a framework agreement that covers 3 R&D phases. The 3 phases are:

— R&D up to solution design,

— R&D up to a prototype,

— R&D up to original development, validation and testing of a limited set of first products or services.

Testing is expected to take place in the facilities of the members of the buyers group FMT, PAT and Helios.

This testing may also serve as a first customer test reference for the contractors. The procurement – from the tender procedure until the subsequent performance of contracts – is expected to start in 28.7.2019 and to end in 31.8.2021.

The selected operators will retain ownership of the Intellectual Property Rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions beyond the procurers.

Valor estimado sin IVA: 2848450.41 EUR 💰
Duración: 19 meses
Nombre del proyecto o programa financiado por la UE: This procurement receives funding from the European Union’s Horizon 2020 Research and Innovation Programme (H2020-EU.2.1. - INDUSTRIAL LEADERSHIP- Leadership in enabling and industrial technologies- Information and Communication Technologies (ICT)) under Grant Agreement No.688878. The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.
Lugar de ejecución
Emplazamiento principal o lugar de actuación:

For each Phase at least 51 % of the R&D services need to be performed within the EU Member States, or a country that is associated to the Horizon 2020.

Información jurídica, económica, financiera y técnica
Ejecución del contrato
Condiciones de ejecución del contrato:

For each Phase at least 51 % of the R&D services need to be performed within the EU Member States, or a country that is associated to the Horizon 2020.

Procedimiento
Base jurídica: 32014L0024
Número de participantes previsto: 4
Hora de recepción de las ofertas: 13:00
Lenguas en las que pueden presentarse las ofertas o solicitudes de participación: inglés 🗣️
español 🗣️

+ 1 más

catalán 🗣️

Plazo de validez de la oferta: 25 meses
Fecha de apertura de ofertas: 2019-10-29 📅
Hora de apertura de ofertas: 13:00
Lugar: C. Roc Boronat, 81-95
08005- Barcelona.

Autoridad contratante
Identidad
Número de registro nacional: Q0801969G
Contacto
Punto de contacto: Pau Aguilar; Ferran Trullàs; Lluis Granero
Dirección del perfil de comprador: https://contractaciopublica.gencat.cat/ecofin_pscp/AppJava/perfil/AQuAS 🌏
URL de los documentos: https://contractaciopublica.gencat.cat/ecofin_pscp/AppJava/perfil/AQuAS 🌏

Referencia
Información complementaria

Participation in the open market consultation that was held as part of the preparation for this procurement is not a prerequisite for submitting a tender.

This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs.

Publication of this Contract Notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation.

The open procedure was chosen in Section IV.1.1) ‘Procedure’ for formal reasons only. This is because it is not possible to publish a contract notice without selecting one of the listed procedures.

Offers may be submitted in English and either Catalan or Spanish (please read the request for tenders document). All communication (before, during and after the procurement) can be made in English, Spanish and Catalan (please read the request for tenders document).

See:

The project website http://antisuperbugs.eu/

The open market consultation Q&A http://antisuperbugs.eu/index.php/market-consultation-2/

PCPs on the Europa website (see https://ec.europa.eu/digital-single-market/innovation-procurement) or contact:

antisuperbugs.AQUAS@gencat.cat

Información complementaria
Órgano de revisión
Nombre: The Head of the Health Department of the Government of Catalonia (‘Consellera de Salut de la Generalitat de Catalunya’)
Ciudad postal: Barcelona
País: España 🇪🇸
Información sobre los plazos de procedimientos de recurso:

The procurement is exempted from the EU public procurement directives (including the EU procurement remedies directives 89/665/EEC and 92/13/EEC — see above) and the national laws that implement them.

Publication of this notice in the Official Journal is not to be understood as a waiver of this exemption by the contracting authority.

Any legal claim, petition or application for judicial review, with regard to the Anti-Superbugs PCP procedure, whether before civil or administrative courts, shall be made before the Spanish jurisdiction. By submitting a bid, the bidder accepts the exclusive jurisdiction of Spanish courts and waives any other jurisdiction which may correspond to them.

Decisions taken with regard to the selection of bidders, awarding them with Phases 1, 2 or 3 or excluding them from the Anti-Superbugs PCP Procedure should be challenged by means of an administrative remedy (‘recurso de alzada’) before the Head of the Health Department of the Government of Catalonia (‘Consellera de Salut de la Generalitat de Catalunya’) within a period of maximum one month upon the formal notification of the decision. The decision of the head of the health department dismissing the ‘recurso de alzada’ could be challenged before the administrative courts (‘Sala de lo Contencioso Administrativo del Tribunal Superior de Justicia de Cataluña’) within a period of 2 months upon the formal notification of the decision.

Any dispute or claim arising out of or in connection with the execution of the FA or of the Phases contracts entered into between the lead procurer and the contractor, shall be heard by the civil courts (‘Juzgados de Primera Instancia de Barcelona’).

Fuente: OJS 2019/S 142-349721 (2019-07-23)

Anuncio de adjudicación de contrato (2020-03-17)
Objeto
Alcance de la contratación
Breve descripción:

This contract notice invites interested operators to submit tenders to a procurement. The procurement aims to trigger new solutions to be developed and tested to address the following challenges: — reducing both the healthcare and governmental costs and the operational impact resulting from infections caused by MDROs; — improving the appropriateness and effectiveness of antimicrobial medicine usage; — reducing the community and social care impact of MDROs acquired at hospitals through technologies that will transform current surveillance and infections control systems into new comprehensive systems. This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).

Valor total de la contratación: 2848450.41 EUR 💰
Metadatos del anuncio
Tipo de documento: Anuncio de adjudicación de contrato

Procedimiento
Tipo de oferta: No procede

Referencia
Fechas
Fecha de envío: 2020-03-17 📅
Fecha de publicación: 2020-03-19 📅
Identificadores
Número de anuncio: 2020/S 056-133247
Se refiere al anuncio: 2019/S 142-349721
Número del DO-S: 56
Información complementaria

Participation in the open market consultation that was held as part of the preparation for this procurement is not a prerequisite for submitting a tender. This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs. Publication of this contract notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation. The open procedure was chosen in Section IV.1.1) ‘Procedure’ for formal reasons only. This is because it is not possible to publish a contract notice without selecting one of the listed procedures. Offers may be submitted in English and either Catalan or Spanish (please read the Request for Tenders document). All communication (before, during and after the procurement) can be made in English, Spanish and Catalan (please read the request for tenders document) See: The project website http://antisuperbugs.eu/ The open market consultation Q&A http://antisuperbugs.eu/index.php/market-consultation-2/ PCPs on the Europa website (see https://ec.europa.eu/digital-single-market/innovation-procurement) or contact: antisuperbugs.AQUAS@gencat.cat

Objeto
Alcance de la contratación
Breve descripción:

This contract notice invites interested operators to submit tenders to a procurement.

— reducing both the healthcare and governmental costs and the operational impact resulting from infections caused by MDROs;

— improving the appropriateness and effectiveness of antimicrobial medicine usage;

— reducing the community and social care impact of MDROs acquired at hospitals through technologies that will transform current surveillance and infections control systems into new comprehensive systems.

This is a joint procurement involving different countries and the state applicable national procurement law is the Spanish one.

• ICO/ VINCat (Catalan Institute of Oncology/Catalan Nosocomial Infections Surveillance). Spain

• UKA (Aachen University Hospital). Germany

• STH (Sheffield Teaching Hospitals NHS Foundation Trust. UK

• PAT (Provincia Autonoma di Trento). Italy

• HELIOS (HELIOS Universitätsklinikum Wuppertal). Germany

• FMT (Fundació Mutua de Terrassa). Spain.

The Lead Procurer is not part of the Buyers Group.

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.

— R&D up to solution design

— R&D up to a prototype

Testing is expected to take place in the facilities of the members of the Buyers Group FMT, PAT and HELIOS.

The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions beyond the procurers

Nombre del proyecto o programa financiado por la UE: This procurement receives funding from the European Union’s Horizon 2020 Research and Innovation Programme (H2020-EU.2.1. — Industrial Leadership — leadership in enabling and industrial technologies- Information and Communication Technologies (ICT)) under Grant Agreement No 688878. The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.

Procedimiento
Criterios de adjudicación
Criterio de calidad (nombre): Technical offer
Criterio de calidad (ponderación): 90
Criterio de coste (nombre): Financial offer
Criterio de coste (ponderación): 10

Adjudicación del contrato
Fecha de celebración del contrato: 2020-03-12 📅
Nombre: Tech4care SRL
Ciudad postal: Falconara Marittima
País: Italia 🇮🇹
Nombre: Culture (Bahia-Gradiant-INL)
Ciudad postal: Ames
País: España 🇪🇸
Nombre: Bugwatcher
Ciudad postal: Sant Cugat
Nombre: ASB- IMS2
Ciudad postal: Dortmund
País: Alemania 🇩🇪
Valor total de la contratación: 2848450.41 EUR 💰
Información sobre licitaciones
Número de ofertas recibidas: 6

Referencia
Información complementaria

Publication of this contract notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation.

Offers may be submitted in English and either Catalan or Spanish (please read the Request for Tenders document). All communication (before, during and after the procurement) can be made in English, Spanish and Catalan (please read the request for tenders document)

Información complementaria
Órgano de revisión
Información sobre los plazos de procedimientos de recurso:

Any legal claim, petition or application for judicial review, with regard to the Anti-Superbugs PCP Procedure, whether before civil or administrative courts, shall be made before the Spanish jurisdiction. By submitting a bid, the bidder accepts the exclusive jurisdiction of Spanish courts and waives any other jurisdiction which may correspond to them.

Decisions taken with regard to the selection of Bidders, awarding them with Phases 1, 2 or 3 or excluding them from the Anti-Superbugs PCP Procedure should be challenged by means of an administrative remedy (‘recurso de alzada’) before the Head of the Health Department of the Government of Catalonia (‘Consellera de Salut de la Generalitat de Catalunya’) within a period of maximum one month upon the formal notification of the decision. The decision of the Head of the Health Department dismissing the ‘recurso de alzada’ could be challenged before the Administrative Courts (‘Sala de lo Contencioso Administrativo del Tribunal Superior de Justicia de Cataluña’) within a period of 2 months upon the formal notification of the decision.

Any dispute or claim arising out of or in connection with the execution of the FA or of the phases contracts entered into between the lead procurer and the contractor, shall be heard by the Civil Courts (‘Juzgados de Primera Instancia de Barcelona’).

Fuente: OJS 2020/S 056-133247 (2020-03-17)

Nuevas adquisiciones en categorías afines 🆕

Servicios de investigación y desarrollo y servicios de consultoría conexos (13 nuevas adquisiciones)

Servicios de investigación y desarrollo experimental (7)